Emergent BioSolutions (NYSE:EBS) Raised to “Buy” at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

Other research analysts also recently issued reports about the stock. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark lifted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 2.9 %

NYSE EBS opened at $8.44 on Thursday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The company’s 50 day simple moving average is $9.35 and its 200 day simple moving average is $8.67. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10. The company has a market capitalization of $457.28 million, a P/E ratio of -2.06 and a beta of 1.59.

Institutional Trading of Emergent BioSolutions

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Emergent BioSolutions by 14.7% in the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after acquiring an additional 436,911 shares during the last quarter. State Street Corp lifted its stake in shares of Emergent BioSolutions by 864.7% in the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP acquired a new stake in shares of Emergent BioSolutions in the third quarter worth $9,296,000. Millennium Management LLC lifted its stake in shares of Emergent BioSolutions by 5.8% in the second quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 52,144 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Emergent BioSolutions by 240.9% in the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after buying an additional 623,201 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.